NO20001479L - Behandling av atferdsforstyrrelse - Google Patents

Behandling av atferdsforstyrrelse

Info

Publication number
NO20001479L
NO20001479L NO20001479A NO20001479A NO20001479L NO 20001479 L NO20001479 L NO 20001479L NO 20001479 A NO20001479 A NO 20001479A NO 20001479 A NO20001479 A NO 20001479A NO 20001479 L NO20001479 L NO 20001479L
Authority
NO
Norway
Prior art keywords
treatment
behavioral disorder
behavioral
disorder
Prior art date
Application number
NO20001479A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001479D0 (no
Inventor
John Harrison Heiligenstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20001479L publication Critical patent/NO20001479L/no
Publication of NO20001479D0 publication Critical patent/NO20001479D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20001479A 1997-09-23 2000-03-22 Behandling av atferdsforstyrrelse NO20001479D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5962897P 1997-09-23 1997-09-23
PCT/US1998/018103 WO1999015163A1 (en) 1997-09-23 1998-09-01 Treatment of conduct disorder

Publications (2)

Publication Number Publication Date
NO20001479L true NO20001479L (no) 2000-03-22
NO20001479D0 NO20001479D0 (no) 2000-03-22

Family

ID=22024194

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001479A NO20001479D0 (no) 1997-09-23 2000-03-22 Behandling av atferdsforstyrrelse

Country Status (17)

Country Link
US (1) US6184222B1 (xx)
EP (1) EP0919235A1 (xx)
JP (1) JP2001517619A (xx)
KR (1) KR20010024219A (xx)
CN (2) CN1762338A (xx)
AU (1) AU740192B2 (xx)
BR (1) BR9812371A (xx)
CA (1) CA2304657C (xx)
EA (1) EA002804B1 (xx)
HU (1) HUP0004025A3 (xx)
IL (1) IL134718A0 (xx)
NO (1) NO20001479D0 (xx)
NZ (1) NZ502853A (xx)
PL (1) PL339425A1 (xx)
TR (1) TR200000756T2 (xx)
UA (1) UA57107C2 (xx)
WO (1) WO1999015163A1 (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100398791B1 (ko) * 1998-04-24 2003-09-19 스카리스타 리미티드 우울증 치료 및 그 용도의 약리학적 제제
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
ATE305307T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von migränekopfschmerzen
EP1629843A3 (en) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Company LLC Reboxetine for treating chronic fatigue syndrome
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6613763B2 (en) 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
EP1414343B1 (en) * 2001-07-11 2009-06-03 CNS Response, Inc. Method for predicting outcome of treatments
US6700018B2 (en) * 2001-07-17 2004-03-02 Mayo Foundation For Medical Education And Research Amine compounds and inhibiting neurotransmitter reuptake
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1482921A1 (en) * 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
EP1494664A2 (en) * 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
JP4563172B2 (ja) * 2002-06-17 2010-10-13 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ レボキセチンの医薬用塩
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US6943193B1 (en) * 2003-01-21 2005-09-13 Jordan A. Altabet Method for treating sexual dysfunction
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
ES2310715T3 (es) * 2003-02-14 2009-01-16 Pierre Fabre Medicament Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
WO2005021095A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
ES2390879T3 (es) * 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
WO2005120200A2 (en) * 2004-06-07 2005-12-22 Mayo Foundation For Medical Education And Research Amine compounds and inhibiting neurotransmitter reuptake
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US8865937B2 (en) * 2009-11-06 2014-10-21 Mahendra G. Dedhiya Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
EP2993213B1 (en) * 2013-04-30 2020-07-15 AGC Inc. Composition containing trifluoroethylene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EA000856B1 (ru) * 1995-07-24 2000-06-26 Эли Лилли Энд Компани Способ лечения синдрома дефицита внимания/гиперактивности
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
EA002804B1 (ru) 2002-10-31
HUP0004025A3 (en) 2002-02-28
AU9041798A (en) 1999-04-12
IL134718A0 (en) 2001-04-30
WO1999015163A1 (en) 1999-04-01
US6184222B1 (en) 2001-02-06
AU740192B2 (en) 2001-11-01
PL339425A1 (en) 2000-12-18
EP0919235A1 (en) 1999-06-02
TR200000756T2 (tr) 2000-09-21
CA2304657A1 (en) 1999-04-01
CN1271278A (zh) 2000-10-25
BR9812371A (pt) 2000-09-19
JP2001517619A (ja) 2001-10-09
UA57107C2 (uk) 2003-06-16
CN1762338A (zh) 2006-04-26
CA2304657C (en) 2005-10-25
NZ502853A (en) 2002-08-28
NO20001479D0 (no) 2000-03-22
HUP0004025A2 (hu) 2002-01-28
KR20010024219A (ko) 2001-03-26
EA200000351A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
NO20001479D0 (no) Behandling av atferdsforstyrrelse
NO995852L (no) Ny form av S-omeprazol
NO973928L (no) Behandling av oljebrönn
ID25504A (id) Pencegahan dan pengobatan penyakit amiloidogenik
DE69631514D1 (de) Steuerbarer katheter
NO982172D0 (no) Anvendelse av epinastin for behandling av smerter
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
NO20001458D0 (no) Behandling av opposisjonstrassforstyrrelse
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
NO965564D0 (no) Medisinsk anvendelse av bromelain
DE59609662D1 (de) Haarbehandlungsmittel
DE19681419T1 (de) Behandlungssystem
NO975718L (no) Behandling av insulinresistens
NO970198L (no) Anvendelse av glyceryltriacetat for behandling av onychomykoser
DE69636841D1 (de) Entwicklungsgerät und Bilderzeugungsapparat
FI974244A0 (fi) Foerfarande foer kompressering av en bild
NO982582D0 (no) FremgangsmÕte for behandling av smerte
NO982562D0 (no) Sammensetning for behandling av smerte
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
NO963482D0 (no) Medisinsk anvendelse av bromelain
NO994526L (no) Fremgangsmaate for stimulering av neural regenerering
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
DE59607418D1 (de) Haarbehandlungsmittel
NO20000274D0 (no) Behandling av fluider
ID17459A (id) Unsur-unsur pengobatan

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application